TOKYO -- Japanese materials maker AGC aims to begin domestic production of messenger RNA, used in manufacturing COVID-19 vaccines, as early as 2025, Nikkei has learned.
The company plans to supply the ingredient to Japanese pharmaceutical firms such as Daiichi Sankyo that are developing locally produced vaccines. Japan is pushing for domestic development and manufacturing of vaccines as crucial to economic security, and this effort includes mass production of core materials such as mRNA.
